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Abstract 
With the continued increase in the use of Bayesian methods in drug development, there is a 
need for statisticians to have tools to develop robust and defensible informative prior 
distributions. Whilst relevant empirical data should, where possible, provide the basis for 
such priors, it is often the case that limitations in data and/or our understanding may preclude 
direct construction of a data-based prior. Formal expert elicitation methods are a key 
technique that can be used to determine priors in these situations. Within GlaxoSmithKline 
(GSK), we have adopted a structured approach to prior elicitation based on the SHELF 
elicitation framework, and routinely use this in conjunction with calculation of probability of 
success (assurance) of the next study(s) to inform internal decision making at key project 
milestones. The aim of this paper is to share our experiences of embedding the use of prior 
elicitation within a large pharmaceutical company, highlighting both the benefits and 
challenges of prior elicitation through a series of case studies.  We have found that putting 
team beliefs into the shape of a quantitative probability distribution provides a firm anchor 
for all internal decision making, enabling teams to provide investment boards with formally 
appropriate estimates of the probability of trial success as well as robust plans for interim 
decision rules where appropriate. As an added benefit, the elicitation process provides 
transparency about the beliefs and risks of the potential medicine, ultimately enabling better 
portfolio and company-wide decision making. 
 
1. INTRODUCTION 
Within the pharmaceutical industry, Bayesian methods are increasingly utilised for statistical 
analyses or to aid design of future studies (e.g. via the assessment of assurance [1] or 
decision-criteria operating characteristics). One key challenge when using Bayesian methods 
is the selection of the prior. In some instances data in a similar setting has been previously 
generated and can be used directly to construct a prior. However, there are generally 
differences between trials (e.g. different populations, endpoints, durations etc.), the impact of 
which can be difficult to quantify directly, and additional data may exist (from other 
compounds or other indications, pre-clinical data etc) that would be problematic to formulate 
mathematically into a prior. In other settings (e.g. novel mechanism of action, novel 
endpoint) there may be little or no relevant data with which to directly formulate a prior. One 
approach to deal with these situations is to draw on expert knowledge and experience to 
“translate” the available information into a prior distribution. At GSK we have adopted a 
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formal prior elicitation framework proposed by Oakley and O’Hagan [2] known as SHELF. It 
has now become routine for teams to use this approach in conjunction with the calculation of 
assurance [1] at key decision milestones. Here the probability of success (assurance) of the 
next study is determined by weighting the conditional likelihood of success (e.g. power) for 
fixed effect sizes by a prior distribution for the true value of the treatment effect of interest.  
The aim of this paper is to share our experiences of adopting a formal prior elicitation process 
at GSK, which we have applied to over 30 studies during 2015-16. We will first provide a 
brief introduction to the SHELF prior elicitation framework (Section 2) followed by a 
discussion of the benefits (Section 3) and challenges (Sections 4 and 5) of conducting prior 
elicitations, and our experiences of how to structure the quantities to be elicited (Section 6).  
We then present a series of case studies to highlight some specific benefits and challenges 
(Section 7).  Finally, we provide some additional thoughts on our experiences with elicitation 
as well as comment on how elicitation is being utilized elsewhere (Sections 8 and 9).  
Additionally, a companion paper [3] in this journal provides similar details of how GSK uses 
a standardised assessment of assurance for all key decisions on investment for future trials. 
 
2. PRIOR ELICITATION FRAMEWORK 
Elicitation is an interview process in which experts are asked a series of questions about their 
beliefs regarding one or more uncertain quantities (e.g. about a mean treatment effect).  
Based on each expert’s responses to these questions, the statistician will then derive a 
probability distribution for the quantity of interest that reflects what the expert believes about 
the value of the quantity as well as the uncertainty of that belief.  The SHELF process 
developed by Oakley and O’Hagan [2] uses a structured approach to prior elicitation that is 
summarised in Table 1. 
Table 1: Main steps in SHELF elicitation process 
1. Select experts These can be both internal and external to the company and should 
involve only those that have a good understanding of the details that 
need to be elicited. 
2. Train experts Provide experts with an overview of the elicitation process and the use 
of subjective probabilities and probability distributions 
3. Evidence 
dossier 
Prepare and review an evidence dossier that captures all pertinent 
information that the experts would rely upon to formulate their opinion. 
4. Elicit 
individual 
priors 
Elicit, in a masked fashion, individual priors from each expert (i.e. 
experts are unaware of what other experts believe at this point) 
5. Discuss 
individual 
priors  
Share and review results from individual elicitations including each 
expert’s rationale for their beliefs; discuss differences between experts. 
6. Agree 
consensus prior 
Where possible, elicit a ‘consensus’ prior from the experts which is 
based on what they collectively agree a ‘Rational Independent Observer’ 
would determine after having observed the previous conversations. 
7. Documentation Provide a written record of the elicitation session 
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For both the elicitation of the individual priors and the consensus, different techniques are 
defined in SHELF including elicitation of tertiles or quartiles, roulette and probability based 
elicitation. We have used both quartiles and roulette methods to elicit individual priors, with 
the latter being our preferred approach as experts find it more intuitive to use.   To elicit the 
consensus prior, we use the probability method, as we have found it more conducive for a 
group discussion.  A brief description of the three methods are presented below; see [2] for 
more details.     
The quartile method requires experts to provide the 25th, 50th and 75th quartile values of their 
belief about the true value of the unknown parameter.   The roulette method requires experts 
to use “chips” to build a histogram to represent their beliefs about the true value of the 
unknown parameter.  The probability method requires experts to provide probabilities that 
the true value of the unknown parameter is less than each of three distinct values (e.g. X1 < 
X2 < X3). 
During the elicitation process it is critical to provide real-time feedback to the experts 
regarding their individual beliefs/priors as well as the resultant consensus prior. As part of the 
SHELF procedure, an R Package [4] has been developed that provides real-time visualisation 
of both individual and consensus elicited curves by selecting the parametric probability 
distribution (e.g. normal, log-normal, etc) which most closely matches the elicited values. A 
key feature of the SHELF approach is the role of the facilitator who has expertise in the 
process of elicitation. The facilitator guides the experts, manages the process to ensure that all 
viewpoints are shared and debated, and at the end delivers the fitted probability 
distribution(s) representing the experts’ beliefs. The facilitator has a critical role in navigating 
the numerous challenges that can arise during an elicitation. Elicitations carried out at GSK 
typically have two facilitators, one to lead the overall process and one to record key details of 
the elicitation session and run the software to fit probability distributions to the values elicited 
from the experts.  
3. USES AND BENEFITS OF PRIOR ELICITATION IN 
DECISION MAKING  
In addition to quantifying expert knowledge into a probability distribution that can be utilized 
in a Bayesian framework, we have found multiple other benefits of adopting a formal prior-
elicitation process.  
3.1. More transparent calculation and communication of Probability of 
Success 
At GSK, at key milestones in development, internal scientific and investment boards review 
both the scientific and financial plans for teams seeking investment to the next stage of drug 
development, where information on the probability of success for both the next trial and 
development plans as a whole is considered. To aid these reviews, teams are expected to 
discuss with these governance boards details of assurance estimates together with the 
underlying prior distribution, for all key milestones. Underpinning this is the choice of prior, 
which is frequently determined via prior elicitation. The elicitation process highlights not 
only the rationale for believing in the likely effect of the drug, but the gaps in knowledge 
and/or sources of uncertainty. Ultimately this has enabled more robust portfolio decisions to 
be made and, where necessary, led to changes in development plans where risk mitigation has 
been needed as a consequence (e.g. agreement for staged investment or adoption of futility 
rules in the next trial). 
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3.2. Improvements in Study Designs 
Discussion of the evidence dossier and each expert’s individual prior distribution may reveal 
aspects of the study design that could compromise the robustness of the study, and which had 
not been considered previously. For example, different beliefs about a treatment effect may 
be driven by opinions on target patient population or other design factors such as use of 
rescue/concomitant medication (see Case Study 2 for an example). Prior elicitation provides a 
mechanism by which teams are able to identify these issues and their potential impact on 
study success, and to subsequently address them in the study protocol.   
In cases where the elicited prior represents a reasonable probability that the treatment effect 
will be negligible or not clinically meaningful, teams may consider study design features (e.g. 
interim analyses) and/or clinical development plan options (e.g. conducting studies in parallel 
or sequentially) to help mitigate key uncertainties (see Case Study 1). The elicited prior 
distribution can be used to assess various study designs (e.g. number of interims and sample 
size at interims) and decision rules, in order to find the design that provides the optimal 
statistical operating characteristics (e.g. probability of making a correct ‘go’ or ‘no go’ 
decision). 
More generally, elicited priors have been used extensively at GSK in clinical trial simulations 
to assess operating characteristics of different trial designs, such as to calculate series of 
assurance estimates to assess the impact of different sample sizes and alternative definitions 
of the end of study success criterion, or to compare overall probability of success for different 
testing hierarchies when multiple endpoints are of interest. See [3] for some further examples.  
3.3. Deeper Understanding 
Perhaps most importantly, we have found that the prior elicitation process has facilitated rich 
and scientifically-driven reviews of evidence, enabling more robust collective understanding 
and decision making. Although experts have the same data and information in front of them, 
they often independently formulate different conclusions. Formal, facilitated prior elicitation 
sessions have enabled the experts to have deeper discussions about the existing knowledge 
and data, and to probe to understand why some experts may place more weight on certain 
evidence compared to other experts. This allows the experts to identify any gaps in their 
knowledge and/or sources of uncertainty, leading to the experts debating the evidence 
robustly. Previously, study teams at GSK were having some discussion but not to the extent 
now routinely achieved during a formal prior elicitation session, and they were generally not 
critiquing evidence as deeply. 
 
4. TECHNICAL AND STATISTICAL CHALLENGES WITH 
PRIOR ELICITATION  
There are many technical and statistical challenges which can lead to bias in prior elicitation 
sessions [5].  It is important to be aware and proactively address these when running the 
elicitation process. The use of the SHELF protocol can help with this. Here we highlight 
some specific challenges that we have encountered which require careful consideration, and 
propose some strategies and solutions to minimise or overcome these. 
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4.1. Aspiration vs belief 
Biases can arise particularly in situations where data are sparse. For example, in early-phase 
clinical studies where limited or no data exist, we have found that without careful guidance 
experts can provide priors representing treatment effects that they want to observe rather than 
what they currently believe the true effect to be. Experts often struggle with the concept of 
eliciting the ‘true’ treatment effect and risk bringing sampling uncertainty and aspirational 
beliefs into the elicited prior. Thorough training of experts is critical to minimise such risks. 
The facilitator needs to concentrate on the language of the experts and the scientific rationale 
for their beliefs, and challenge the experts if necessary to ensure the ‘what they want to see’ 
aspect does not creep into the process.   
4.2. Over-optimism 
Careful selection of experts is paramount to a successful prior elicitation session. Many of the 
experts are likely to be either Key Opinion Leaders (KOLs)/treating physicians or members 
from the project team. In this situation the facilitator needs to ensure that the experts do not 
either intentionally or unintentionally give over-optimistic views. One aspect of the SHELF 
process is to document any potential sources of known biases (e.g. conflicts of interest) to 
create transparency. The facilitator should also ensure that experts justify their opinions 
during the feedback and discussion following the individual prior elicitations. Benchmarking 
the expert’s opinion with ‘portfolio priors’ can also be helpful. Simply sharing with the 
experts the overall success rates for assets at a particular stage of development within either 
the disease area or the broader industry level (e.g. [6]) can help experts better calibrate risks 
of novel mechanisms not translating to clinical efficacy. 
A related problem is that standard elicitation approaches require experts to provide a uni-
modal distribution.  Experts may have some belief that the true drug effect could be near zero 
but think it is implausible for it to be negative/unfavourable. As a result, experts may tend to 
push their distribution towards more positive results to avoid parts of the fitted distribution 
being negative. Fitting a bounded or truncated distribution can help, but this can still fail to 
adequately capture the expert’s beliefs about the most likely values whilst still having 
sufficient probability of near-zero (or negative) effects. We have found that a better solution 
can often be to elicit a bi-modal prior distribution (see section 6.3 and Case Study 3).   
4.3. Challenges reaching consensus 
The SHELF process defines what is called a ‘consensus’ prior, using a behavioural 
aggregation approach [2]. Following the elicitation and discussion of each expert’s individual 
prior, experts are then asked to collectively agree a consensus prior representing what a 
‘Rational Independent Observer’ (RIO) would determine after having observed the previous 
conversations. This requires the experts to implicitly agree on how much weight should be 
given to each of their individual priors and supporting arguments; it does not (and should not) 
require each expert to accept the RIO consensus as their own personal prior belief. However, 
in some instances we have found that either experts cannot put aside their beliefs or there are 
fundamental and valid differences in opinions. Ultimately, failure to reach a consensus has 
not proved to be a major issue, provided the elicitation exercise can formulate why 
differences occur. In these situations we have found that eliciting two (or more) separate 
priors based on the differing opinions and providing a clear supporting rationale can be very 
helpful to decision makers and governance boards, so that open and transparent review of 
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risks can then be held based on the feedback from the elicitation - see Case Study 2 (section 
7.2) for an example.   
Alternatively, a consensus prior can be derived by mathematical pooling of the experts’ 
individual priors.  We do not recommend this in situations in which there are strong 
differences of opinion between experts, since a mathematical average can end up representing 
no-one’s beliefs in particular.  However, when there is a high degree of overlap of all the 
experts’ individual priors, mathematical pooling (using a simple average of the individual 
priors) can be an efficient and acceptable method to achieve a consensus prior. In such 
situations, after first explaining the purpose of the consensus prior to the experts, we may 
choose to show them the mathematically pooled prior and ask if they all agree that this 
provides a reasonable representation of what an independent observer might believe.   
4.4. Risk of experts misunderstanding statistical quantities 
To run a successful elicitation process the experts require a good understanding of both 
probability and other statistical terms (e.g. quartiles). When we originally piloted prior 
elicitation, we started with the quartile approach for individual elicitations. Here we required 
the experts to give their median, lower 25% and upper 75% quartiles for the true value of the 
quantity of interest. It was clear that some experts didn’t have a good conceptualisation of 
these terms, leading at times to ‘U’ shaped distributions which, when reviewed, did not in any 
way represent their beliefs. Through careful education using an initial training session we 
were able to overcome some of these misunderstandings; however we still at times 
encountered problems with distributions not truly matching the expert’s belief. Partly for this 
reason, our preferred method for eliciting individual expert priors is the roulette approach, 
which experts find more intuitive and is less prone to misunderstanding.  
Another issue is that experts often struggle with the concept of eliciting the ‘true’ treatment 
effect and risk bringing in sampling uncertainty into the elicited prior.   Clarity in the training 
of experts to ensure that they understand what is meant by ‘true effect’ (e.g. result of the 
infinitely sized clinical trial) and other statistical concepts is critical to minimise such risks. 
 
4.5. Risk of experts providing symmetrical ‘bell-shaped’ 
distributions 
Although there is nothing wrong with an expert providing a symmetric ‘bell-shaped’ 
distribution for their beliefs, we have found that experts often feel that this is required, having 
been continually presented with normal distributions during statistical training. When using 
techniques such as the roulette method we are careful to ensure that experts understand that 
their distributions do not have to be symmetrical (by highlighting both symmetric and non-
symmetric examples during training) and should truly reflect their beliefs. The role of the 
facilitator is also extremely important here: during the elicitation, he/she should ask questions 
around each expert’s prior – focusing not only where the distribution is centered but also on 
the tails of the distribution – to ensure it truly matches the expert’s belief. 
 
7 
 
5. PRACTICAL AND LOGISTICAL CHALLENGES WITH PRIOR 
ELICITATION  
5.1. Choice of experts 
One key aspect of a prior elicitation is the selection of experts. Individuals with the relevant 
experience and expertise are often members of the project team or KOLs who may have a 
vested interest in the running of the trial (e.g. unmet need for patients).  Although there is 
nothing wrong with such individuals being experts for the elicitation process, there is an 
expectation of unconscious bias based on their experiences and backgrounds with the 
potential to lead to over-optimism.  In sessions we have run, we have tried to be 
comprehensive in the selection of experts, aiming to get at least some experts (internal or 
external to the company) who are independent of the project if possible. We also typically 
include a statistician who has in-depth knowledge of the project or related development 
programmes; he/she brings both a detailed understanding of the relevant data and expertise in 
expressing judgements and uncertainty in the form of probabilistic statements. There is no 
ideal solution to the balance between expertise and impartiality when selecting the experts, 
and having a skilled facilitator is critical to ensure experts’ in-depth knowledge is brought to 
the prior elicitation process effectively in an unbiased fashion. 
 
5.2. Complexities of running elicitation sessions when experts are 
located remotely. 
It is common that experts work internationally across multiple continents and this poses 
logistical challenges for running an elicitation. Given the psychological aspect of prior 
elicitations, face-to-face interactions are preferable. Therefore, we have tended to utilise 
video-conferencing to try to engage virtual face-to-face elicitations. Additionally, we have 
had an experienced facilitator at each location to assist the lead facilitator in managing and 
‘reading’ the room. 
 
5.3. Evolving project planning 
In reality, developing study plans can be iterative in nature, with changes to study design 
occurring until late in the protocol development. When using prior elicitation to determine 
estimates of assurance, all key aspects of the design need to be well defined. Even during the 
elicitation session itself, key facets of the design that impact on the expected treatment effect 
can arise which may necessitate adapting the details of what is to be elicited.  
One particular observation is that experts may disagree with the populations proposed and 
believe that with a different population the probability of success could increase.  It is critical 
that all experts have a precise understanding of the study design to which the elicitation 
relates (including targeted population) and if changes are needed they are made before the 
experts give their priors. For example, during the review of the evidence package for an 
elicitation to support a proposed paediatric study, one of the experts (external to the 
project/study team) noted that, based on the targeted population, the likelihood of the 
treatment effect being positive was unlikely and a more uncontrolled population would 
significantly increase likelihood of success. Following a discussion, the experts agreed that 
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the drug needed to be studied in a more uncontrolled population, and so the experts were 
asked to provide their priors for the true treatment effect in this new population. 
5.4. Software 
It is important to be able to provide real-time feedback on both the individual and consensus 
priors.  The R package [4] provided as part of the SHELF protocol has been a very useful 
tool, which we have enhanced by building a SHINY interface [7].  The interface provides 
faster and improved graphical representation of both individual and consensus priors, and has 
been tailored for the process of recording the information elicited from experts.  Additionally, 
the tool has extra outputs that we have found to be useful, including presenting elicited priors 
on different scales (e.g. presenting the implied prior for active arm response if the elicited 
quantities are the control arm response and the treatment difference; presenting elicited priors 
for active and control rates on a hazard ratio scale or vice-versa). 
 
6. STRUCTURING THE ELICITATION PROBLEM 
6.1. Defining the quantities to elicit 
Before conducting an elicitation, the facilitator needs a clear understanding of the statistical 
model or decision problem of interest and the uncertain quantity(ies) for which an elicited 
probability distribution is required.  Often the parameter of interest is a measure of the 
treatment effect relative to the control. This could be the absolute difference between the 
treatment and control, a relative treatment difference or the hazard ratio (i.e. time to event 
outcome).  
Having established the statistical quantities of interest, it is then necessary to determine what 
exactly the experts will be asked to elicit. The elicitation variables should be defined in such a 
way that the expert is able to apply his/her knowledge as directly and fully as possible without 
necessitating ‘mental gymnastics’. This can vary between experts, and can depend on the nature 
of the available evidence that the experts are drawing on. For example, for an elicitation carried 
out to inform a cardiovascular outcomes trial, the main source of evidence comprised several 
previous trials reporting the hazard ratio for the same endpoint for competitor molecules. Experts 
therefore felt comfortable directly eliciting their beliefs about the hazard ratio. On the other hand, 
in an elicitation for a rare disease with a novel endpoint, no previous comparative studies were 
available and the only relevant evidence was on disease progression rates from a natural history 
study, plus some limited PK-PD data on the molecule of interest. We therefore chose to elicit 
experts’ beliefs about: (1) the proportion of patients who would progress by 18 months on 
placebo; (2) the (relative) difference in this proportion between active and placebo. Under the 
assumption of exponential event times, these two quantities together determine an implicit prior 
for the hazard ratio that can be used for assurance calculations [8].    
 
6.2. Eliciting correlated quantities 
In situations where we are eliciting expert beliefs about both control and active responses, it is 
often the case that what an expert believes about the response on treatment will depend on what 
he/she believes about the control response. In such situations, it is important to recognise this 
potential dependence when structuring the elicitation problem. One way to address this is to ask 
the experts to assume a particular value for the control response (typically, the mean or mode of 
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the elicited control prior), and then elicit their beliefs about the active response conditional on the 
fixed control value. This conditional distribution can then be converted into a prior for either the 
relative or absolute treatment difference between active and control, and then combined with the 
prior for the control response to derive an unconditional (but correlated) prior for the active 
response. Alternatively, we often elicit the experts’ beliefs about the absolute or relative treatment 
difference directly. The choice of absolute or relative difference will depend on which measure of 
treatment effect the experts think is most independent of the control response, and this will be 
discussed and agreed with the experts at the start of the elicitation.      
Another scenario involving correlated quantities is elicitation of parameters for dose-response 
modelling. For example, we may require prior distributions for the Emax, E0 and ED50 
parameters of the three-parameter Emax model [9], which are known to be highly correlated. 
Additionally, experts may be unfamiliar and uncomfortable providing beliefs about these 
parameters.  Rather than directly elicit expert beliefs about each of these parameters and their 
dependencies, we follow an approach broadly similar to that of Huson and Kinnersley [10], 
which is to elicit expert beliefs about the true response for each of a pre-specified set of doses 
of interest. We then map these beliefs onto the dose-response model parameters by treating 
the elicited prior for each dose as if it was the sampling distribution for the response at that 
dose and fitting an appropriate Bayesian dose-response model assuming functional uniform 
priors [11]. The resulting joint ‘posterior’ distribution for the model parameters represents the 
implied expert belief distribution for those parameters. Case study 4 in Section 7.4 provides 
an example.  
For all of the above situations, it is useful to be able to derive and show distributions of the 
final parameter of interest (e.g. hazard ratio, absolute difference, mean dose-response curve 
etc) to the experts to ensure it represents their beliefs.  We have adapted our software for this 
purpose (section 5.4).     
 
6.3. Eliciting bi-modal prior distributions 
In many situations there is a reasonable probability that the drug being tested will 
demonstrate no efficacy in the planned endpoint of interest. Furthermore, it may be 
scientifically implausible that the drug being tested will have a true negative effect. As noted 
in section 4.2, in this situation eliciting a uni-modal distribution may not accurately capture 
an expert’s belief about the true effect since there may be insufficient probability around a 
near-zero effect.   
To overcome this issue we have, in a number of elicitations, elicited bi-modal (‘spike and 
smear’) distributions. We do this by 1) eliciting the expert’s probability – w, say - that the 
drug has a true positive/favourable effect, and 2) eliciting the distribution of this effect size 
under the assumption that the drug does have a favourable effect. We then form a mixture 
distribution to represent the overall prior for the treatment effect. For example, if the prior 
conditional on the drug having a favourable effect has been elicited on the scale of the 
treatment difference, we then weight this distribution by a factor (1-w) and add a ‘spike’ with 
weight w at zero (absolute difference) or one (relative difference) to represent the probability 
of no effect.  Figure 1a gives a hypothetical example to illustrate this approach. If a prior for 
the control response has also been elicited, this can be combined with the bimodal prior for 
the treatment difference to provide a mixture prior for the active response which has weight w 
on the control response distribution and weight (1-w) on the conditional distribution for the 
active response (Figure 1b). 
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Figure 1: (a) Illustration of bi-modal ‘spike and smear’ distribution for a treatment 
difference. In this case, experts have given 40% probability that there is no true 
benefit of the drug (represented by spike at zero) and therefore 60% weight to the 
elicited prior conditional on a positive treatment effect. Note that due to the difficulty 
in plotting a mixture of a discrete and continuous distribution (the height of the spike 
is ill-defined), we follow Walley et al [12] and scale the height of the spike to equal its 
probability mass (0.4) and scale the continuous conditional distribution so that its 
maximum equals its total probability (0.6). (b) Illustration of mixture prior for response 
on active treatment. Blue distribution is the elicited prior for the placebo response; 
red distribution the elicited prior for the active response conditional on drug having a 
true benefit; black distribution is the overall distribution for the active response and is 
a mixture of the blue and red distributions with weights 40% (the experts’ consensus 
probability for there being no true benefit) and 60% respectively. 
 
 
 
A useful source of information when eliciting bi-modal priors are statistics on the success 
rates in drug development [6]. Through the use of cross-industry benchmarking of success at 
each stage of drug development we are able to provide experts with background success rates 
for many diseases under consideration for compounds at different stages of drug 
development. These statistics can help calibrate experts’ opinions on the probability of a 
compound failing to demonstrate efficacy. Walley et al [12] used such a ‘portfolio prior’ in a 
case study in which they elicited a prior for the treatment effect in a Proof of Concept study. 
Their approach was to construct a bi-modal – or “spike and smear” – prior by eliciting a 
distribution based on expert beliefs about the treatment effect if the compound was ‘active’, 
and then adding a spike of probability at zero with weight 60%, which they argue is 
comparable with industry attrition rates at this stage of development. In contrast, we have 
found it more useful to use these portfolio success rates as additional background evidence, to 
be taken together with all information on the specific compound of interest that the experts 
synthesize to formulate their prior. This forces experts to robustly articulate and justify if and 
why they believe the probability of a true positive effect is higher for a specific compound 
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than the overall portfolio success rate, which in turn is valuable information for decision 
makers and investment boards when balancing risks across the portfolio.       
 
7. CASE STUDIES 
During 2015-2016 we have conducted over 30 formal prior elicitation sessions using the 
SHELF approach. Elicitations have been run across a variety of therapeutic areas and all 
phases of drug development, with a reasonable balance in numbers across Phases II-IV, plus 
a few at Phase I stage. From these we have selected four case studies that emphasise different 
aspects of both the benefits and challenges with prior elicitation sessions. 
7.1. Case Study 1: Rhinitis study 
This elicitation focussed on a fixed-dose combination (FDC) of two different drugs with 
different mechanisms of action. Positive data were reported in a phase II Proof of Concept 
(PoC) study in an allergen challenge model in which rhinitis patients were exposed to 
controlled amounts of allergen and the effect of the FDC was assessed using symptom scores. 
The next planned study was to assess the FDC in a phase III study assessing rhinitic patients 
in a real-world environmental setting.  In addition to the PoC study, data were also available 
from other similar in-house molecules assessed both in the challenge model as well as an 
environmental setting, plus summary results from a similar FDC in a series of phase III trials.  
This set of data allowed the degree of association between phase III response and PoC 
response to be assessed. 
The team developing the phase III study were required to provide an estimate of assurance to 
seek agreement with internal governance boards to commit to phase III and then to optimise 
the phase III trial based on levels of assurance. It was decided that although there was a 
wealth of available data, there were still uncertainties around what the effect of the FDC 
would be in the setting of Phase III (i.e. environmental setting), so a prior elicitation session 
was conducted. A group of 6 experts were convened for the elicitation, and their individual 
and consensus priors for the treatment difference between the FDC and the corticosteroid 
component are presented in Figure 2.  
In parallel with the elicitation session, a model-based prior was derived based on assuming a 
linear relationship between the PoC and phase III treatment differences. Intercept and slope 
parameters describing this relationship were included in a Bayesian hierarchical model which 
updated vague priors with all available PoC and phase III study results from other 
compounds. The predicted phase III treatment difference based on the PoC data for the 
investigational product was then used as the model-based prior. This model-based prior is 
also shown in Figure 2 (red curve). It is noticeable that this has considerably more uncertainty 
than the experts’ elicited priors. The elicited priors have negligible probability that the 
treatment effect is less than zero (a scientifically implausible result when comparing 
combination to monotherapy), whilst the model based approach suggests this is plausible. 
Conversely, the model-based prior also has considerable probability of a treatment difference 
above 1.0, in contrast with the elicited priors. A benefit of the elicited priors is the fact that 
the experts are able to bring in the broader knowledge of the FDC mechanisms and published 
data on other molecules leading to belief that the effect would be very unlikely to be 
negative, while clinical expertise of the disease informed a maximal plausible efficacy 
threshold.   
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The elicited consensus prior was subsequently used to determine estimates for assurance 
(approximately 55%), which in turn informed the sample size of the Phase III studies as well 
as the overall development strategy.  As a result of quantifying the risk of failure the 
development team favoured a staggered approach to the two phase III studies to mitigate the 
cost and risk of a parallel phase III approach.  The model-based assurance (approximately 
80%) was over-optimistic, and would have led to a less appropriate development plan. See 
[3] for further discussion of the assurance calculations for this Case Study. 
Figure 2: Results from Rhinitis elicitation session 
 
 
7.2. Case Study 2: Rare Disease 
A phase III trial was planned in a rare disease, following positive results seen in Phase III for 
other indications and compassionate use data in the disease area. To determine good 
estimates of the probability of success (assurance) for Phase III a formal prior elicitation was 
conducted. Given the rare diseases nature it was decided to utilise external, as well as 
internal, experts. 
The elicitation focused on the primary endpoint of the proportion of patients who experience 
an exacerbation during the treatment period. The elicitation was structured to first elicit the 
placebo exacerbation responder rate and then to elicit the relative treatment difference (i.e. 
relative risk) conditional on the placebo response. The results of the individual priors elicited 
for placebo are presented in Figure 3, which shows clear disagreement between some of the 
experts. 
Figure 3: Results from Rare Disease elicitation session 
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Following review of each expert’s elicited prior and discussion around the rationale for their 
chosen distribution, it was clear that Expert 2 and Expert 5 had fundamentally different 
beliefs about their placebo response rates. These two experts were both external physicians 
treating this patient population. During the review of the individual priors, Expert 2 stated 
that he/she believed that investigators would be keen to get their patients in the trial due to 
the high un-met need for this disease. Importantly, key inclusion criteria for the study 
protocol defined that patients must be on a stable dose of background therapy for 4 weeks 
prior to randomisation and must have experienced two or more exacerbations in the 12 
months prior to screening. Expert 2’s belief was that investigators who are keen to get 
patients into the trial, could temporarily reduce levels of background therapy in the months 
before the trial to induce the required number of exacerbations to meet protocol inclusion, 
restoring background therapy to the original level for the 4 weeks prior to randomisation and 
for the duration of the study. Thus, the trial could recruit stable patients unlikely to 
exacerbate during the study period. In contrast, Expert 5’s prior distribution is based on the 
assumption that investigators, through training, would understand the study endpoint and the 
target patient population, and hence the population enrolled would be closer to that intended 
by the protocol inclusion criteria. 
Other experts believed that there was some risk of modifying background therapy to ensure 
patients entered trial, but based on the proposed types of clinical sites planned, they thought 
the impact on placebo exacerbation rate would be less extreme than did expert 2. 
Following lengthy discussion between the experts, the potential of how sites would select 
patients was felt to be a clear differentiator to placebo response and so it was agreed to have 
two separate priors for the placebo response.  The first prior was the consensus prior based on 
all individual beliefs excluding expert 5’s belief.  The second was based on expert 5’s beliefs. 
For elicitation of the relative risk, two separate priors were elicited: one conditional on the 
consensus prior from all experts excluding expert 5 and one conditional on experts 5’s prior. 
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The rationale for this was to capture priors conditional on how sites would enrol patients and 
potential risk of background therapy modification. By doing so the experts successfully 
reached consensus for both of these two priors (not shown here). Based on these priors the 
team were able to calculate assurance for the phase III trial for each of the two scenarios. 
At face value this case study could be seen as a failure to identify a consensus placebo prior. 
However, ultimately the benefit of the prior elicitation session was that the team were able to 
have a balanced and transparent discussion at governance boards where quantitative estimates 
of risks were provided for each scenario, allowing for a better understanding of the risks 
depending upon how investigators were likely to recruit patients into the trial.  Furthermore, 
the team was also able to adapt the inclusion/exclusion criteria language to minimise the risks 
identified by Expert 2. 
7.3. Case Study 3: Secondary Indication 
A study was planned in a new indication for a drug already in development. While there was 
strong biologic rationale for believing the medicine would be effective, there was no prior 
clinical data in patients for this new indication.  As such, an elicitation was planned and a 
panel of both internal and external experts was convened.  Several of the experts had 
experience treating the target population which comprised patients who failed 1st line 
treatments (often referred to as 2nd line treatment). The elicitation was structured to elicit the 
response of comparator arm (standard of care, SOC), and then the response of the active arm. 
The individual priors for the SOC response are presented in Figure 4a (coloured curves), in 
which it is clear that there are three factions of beliefs about the SOC response. During the 
discussion of each expert’s rationale for their prior it became apparent that experts were 
considering different patient populations.  The two experts (1 and 2) who strongly believed 
patients would respond to SOC were considering treatment naïve or 1st line patients, based 
on their personal experience of treating patients in primary care.  Conversely, the two experts 
(3 and 5) who strongly believed that patients would not respond to SOC were considering 2nd 
line patients (who would have failed 1st line therapy, SOC) based on their personal 
experience of treating patients in tertiary referral centres.   Realizing the basis for the 
difference of opinion, the facilitator was able to bring the panel to consensus (black curve in 
Figure 4a) by clarifying that the target patient population represented those at the more severe 
end of the disease spectrum who were more likely have an incomplete or no response to 
SOC.   
 
Figure 4: Results from Secondary Indication elicitation session. (a) Individual and 
consensus priors for SoC response rate; (b) Individual and consensus priors for 
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active response rate conditional on drug working; (c) overall bimodal consensus prior 
for active response rate. 
 
 
Once consensus had been achieved for the true response on SOC, the experts were asked to 
provide their beliefs about the true response on the active treatment.   Because of lack of data, 
the experts were first asked to provide their belief regarding the probability that the medicine 
will provide any level of clinical benefit/efficacy.  Then, experts were asked to provide their 
beliefs regarding the true response of the medicine conditional on the medicine having some 
benefit/efficacy.  Following discussion between the facilitator and experts at the start of the 
session, it was agreed that the latter would be elicited on the scale of the response rate itself, 
rather than as a relative or absolute difference in response rates from SOC, because the main 
evidence related to open-label studies and case reports of response rates in a competitor 
molecule. Following elicitation of individual priors, the panel was able to agree on both the 
probability of the medicine providing any benefit (80%), and a consensus prior for the true 
response conditional on the medicine providing benefit (Figure 4b).  In this case, the resulting 
bi-modal distribution for the response rate on active treatment (Figure 4c) was constructed as 
a mixture of this conditional distribution (with weight 80%) and the elicited prior for 
response on SOC (with weight 20%), and was felt by the panel to provide a fair 
representation of their collective beliefs. 
This case study highlights the challenge of ensuring that the quantity to be elicited is clearly 
defined and that all experts understand that definition.  However, through the elicitation 
process and discussion of rationales for individual beliefs, the facilitator was able to identify 
the misunderstandings in the definition of the patient population and help the team come to 
consensus.   It should be noted that it is not always possible to reconcile differences in experts 
beliefs nor is it necessary to do so, as highlighted in the previous case study.  The case study 
also highlights the utility of a bi-modal distribution to allow priors to account for some 
probability that the drug in question may not be effective. 
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7.4. Case Study 4: Dose Response 
The previous examples involved one key treatment comparison of interest. However, in other 
cases, such as dose finding studies, there may be several treatment effects/parameters of 
interest. For this case study, the planned study included 5 doses with the main aim to estimate 
the dose response using a suitable monotonic dose-response model such as a 3-parameter 
Emax [9] model.  In this instance we could have tried to elicit directly the parameters of the 
Emax model. However most experts struggle to understand and translate these parameters to 
match their expert judgment of the dose response profile. Also, there was some uncertainty 
about the most appropriate functional form to select for the dose-response model. Instead, as 
discussed in section 6.2, the responses at selected doses was elicited and then translated in to 
a prior distribution for dose response curves of various functional forms.  While ideally we 
would want to elicit at many dose levels, for pragmatic reasons 3 points of the dose response 
profile (placebo (zero dose), 25 and 50 mg doses) were elicited which allowed us to 
adequately determine an elicited distribution for a range of 1-, 2- and 3-parameter dose-
response profiles. The top dose (50mg) was chosen as the experts believed this would be a 
dose that gave near maximum effect, and was the top dose planned for the study. The 25mg 
dose was chosen as this was the predicted equivalent dose to that had been studied in a 
previous IIa trial (note: there was a change to formulation between Phase IIa trial and planned 
phase IIb trial). Based on the response distributions elicited at these three dose levels, the 
experts were then presented with fitted dose-response profiles and associated uncertainty 
bands for a range of standard models, including linear, log-linear, quadratic, exponential and 
3-parameter Emax. Experts were then asked to collectively agree which of the fitted curves 
most appropriately reflected their beliefs about the likely dose-response profile for the phase 
IIb setting. The consensus priors for each of the 3 doses and the final elicited dose response 
profile are given in Figure 5.  
Figure 5: Results from the Dose Response elicitation session. (a) Consensus priors 
for true response at each of 3 doses. (b) Consensus dose response curve derived 
from elicited priors 
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8. DISCUSSION 
Prior elicitation has become widely used within GSK to derive priors to enable better 
quantification of success (assurance) and for use more generally in drug development (e.g. in 
formal Bayesian analyses either at end of study or to support interim results or in simulations 
to assess different design options). Since instigating an initiative to develop knowledge and 
expertise in this area in 2014, we have to date conducted over 30 elicitations across many 
therapeutic areas. Through this journey of learning by implementation we have identified 
many benefits as well as challenges with prior elicitation. A consistent finding is that prior 
elicitation allows experts to probe deeply their understanding and beliefs, and to thoroughly 
discuss why different experts put different weight on different pieces of evidence. By sharing 
each individual’s elicited prior, the discussions become more focussed and quantitative in 
nature, leading to more robust understanding of risks and, in some instances, insight is gained 
as to how these risks could be mitigated (e.g. Case Study 2). We have found that use of a 
formal prior elicitation session stimulates richer, deeper discussions, leading to a tangible 
benefit over and above the final elicited prior. Teams generally gain a much better 
appreciation of all available evidence and the nuances associated with this information.  
It is important to be able to present complex findings from a prior elicitation session to non-
statisticians, including internal governance boards, in a way that is clearly understood. As a 
result, within GSK we have created a standard template that presents the results of a prior 
elicitation exercise and associated assurance calculations [3].  
One downside of conducting prior elicitation sessions is the time investment required by 
experts and facilitators. Typically, half a day is needed to perform an elicitation exercise. 
This could likely involve experts at multiple sites at geographically diverse locations. It is 
critical that all experts are trained before an elicitation session, which takes approximately 1 
hour to complete. To make the process more efficient we are currently developing a e-
learning module that allows experts to be trained separately to the prior elicitation session at a 
time convenient to them. 
One key concern commonly raised with prior elicitation is the risk of over-optimism. We 
have found that, in some instances, the elicitation of bi-modal distributions can help to some 
extent to mitigate this. Importantly, careful selection and training of experts, structuring and 
facilitation of the elicitation session and documentation of the session can help to further 
reduce these risks. Comparing final data to the prior can be envisaged as one way of 
attempting to review the credibility of the prior, but discordance doesn’t necessarily mean 
that the experts were ‘wrong’. Ultimately we will need to compare across many completed 
studies and assess the overall concordance between priors and final data to start to build a 
picture of the ability of experts to effectively formulate a prior. 
External to GSK, there are several other examples of the use of prior elicitation to inform 
various stages of drug development. For example, Sabin et al [13] highlight how a 
quantitative process has been implemented for drugs entering phase II to help support 
evidence-based decision-making for new drug candidates .The process described shares many 
of the features of the GSK process described here and in our companion paper [3], including 
systematic review of the literature and available evidence, use of expert opinion to inform 
prior distributions on treatment effects, and calculation of probability of success using 
assurance. However, a key difference is in the way prior distributions are constructed and the 
role of expert opinion in this process. Sabin et al’s approach involves eliciting three separate 
prior distributions representing sceptical, optimistic and uninformative opinions, and using 
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these to compute three separate assurance values for future phase III studies. This can be 
helpful to quantify robustness of the decision, but ultimately, one decision, and not three 
decisions must be made, and so the decision maker must choose which prior they want to 
believe. The approach we have implemented at GSK enables us to draw on the experts to 
collectively agree the consensus position to report to decision makers. This is not always 
possible, as illustrated in Case Study 2, in which case multiple priors and associated 
assurances are presented. Critically, however, each different prior and assurance value is 
accompanied by a clear rationale to support the belief, and decision makers can understand 
the extent to which the experts are truly sceptical or optimistic.   
Sabin et al’s approach also differs from ours in that they elicit priors for the phase II 
endpoint, which are then updated with the phase II data once available, and combined where 
necessary with a model-based prediction of the relationship between the phase II and phase 
III endpoint in order to provide a new set of priors for the phase III treatment effect. This has 
the advantage of providing an objective way of incorporating directly relevant data into the 
prior. However, our experience is that the phase III setting often differs from phase II (e.g. 
different endpoints, target populations etc.), and there is often insufficient historical data to 
enable a reliable model-based prediction of the relationship between phase II and III (e.g. 
Case Study 1). A key motivation for developing the GSK prior elicitation process was to 
provide a systematic approach to bridging the translational gap between completed studies 
and planned studies when there is a lack of reliable evidence or scientific consensus, or 
legitimate models are in conflict.   
Walley et al [12] also present a case study to illustrate the benefits of a Bayesian approach to 
decision making for early phase studies. Their case study relates to a proof of concept trial, 
but shares many features of the GSK approach which spans all phases of clinical 
development. In particular, Walley et al also used prior elicitation based on the SHELF 
protocol [2] to construct informative priors for the control response and the treatment effect. 
Similar to our experience, their rationale for using prior elicitation rather than a purely data-
based prior was that the available historical data were either too limited to provide reliable 
estimates or related to a different patient population. In addition, they adopt a bi-modal prior 
for the treatment effect, similar to our Case Study 3, although they base their prior probability 
of clinically relevant treatment effect on the industry-wide success rate for this stage of 
clinical development, rather than eliciting this probability from the experts.  
One difference between Walley et al’s example and our current experience at GSK is that the 
success criteria in Walley et al’s case study were also based on a Bayesian analysis of the 
trial, whereas the majority of case-studies at GSK have used a frequentist analysis and 
success criteria. This partly reflects the stage of development, with many of our examples 
relating to probability of success of phase III designs, where frequentist analyses dominate. 
As yet, there is limited experience of using elicited priors for analysis of clinical trials. 
Walley et al distinguish between design priors and analysis priors, and argue that whilst 
informative priors based on historical data and/or expert opinion can and should be used to 
inform decision about study design, a more cautious, exploratory approach to using 
informative priors for analysis is recommended. An exception is the work by Hampson et al. 
[14], who use expert elicitation to maximise what could be learnt from the analysis of a phase 
III trial for a rare paediatric disease. In such situations, definitive sample sizes for a clinical 
trial are usually infeasible, and Hampson et al argue that eliciting expert opinion about likely 
treatment effects can provide valuable supplemental information that can be updated by 
results from a prospective clinical trial via a fully Bayesian analysis.       
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9. CONCLUSIONS 
High quality decision making is critical to the success of any pharmaceutical company. 
Whilst relevant empirical data should, where possible, provide the evidential basis for such 
decisions, decision making in the pharmaceutical industry is often characterized by multiple 
uncertainties. Prior elicitation is a key tool that allows for capturing current knowledge plus 
appropriate uncertainty to allow for better quantitative decision making, and enables the 
wealth of knowledge, experience and insight of scientists and the medical/scientific 
community to inform such decisions in a rigorous and repeatable way. As an added benefit, 
the elicitation process provides transparency about the beliefs and risks of the potential 
medicine, not only by producing a quantitative belief distribution for the treatment effect(s) 
of interest, but through the process itself, in which all relevant data is summarized, reviewed 
and implicitly weighted and expert opinions are discussed, debated and documented. 
 
At GSK, putting team beliefs into the shape of a probability distribution provides a firm 
anchor for all internal decision making: opinions are challengeable and teams are able to 
provide investment boards with formally appropriate estimates of the probability of trial 
success as well as robust plans for interim decision rules where appropriate, enabling better 
portfolio and company-wide decision making. 
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